Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Finished Goods (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Finished Goods for 4 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods rose 84.19% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 84.19% increase, with the full-year FY2024 number at $2.6 million, up 91.5% from a year prior.
  • Finished Goods was $3.3 million for Q3 2025 at Gyre Therapeutics, down from $3.4 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.4 million in Q2 2025 to a low of $1.4 million in Q4 2023.
  • A 4-year average of $2.3 million and a median of $1.8 million in 2024 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: fell 2.43% in 2023, then surged 122.77% in 2025.
  • Gyre Therapeutics' Finished Goods stood at $1.4 million in 2022, then dropped by 2.43% to $1.4 million in 2023, then skyrocketed by 91.5% to $2.6 million in 2024, then rose by 27.05% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Finished Goods are $3.3 million (Q3 2025), $3.4 million (Q2 2025), and $3.3 million (Q1 2025).